HIV Wasting Syndrome
12
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (12)
A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children
Growth Hormone in the Treatment of HIV-Associated Wasting
A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements
A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss
Nutrition Intervention in AIDS Wasting
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting